Deconstructing the Behavioral Pitch Deck: A Dialogue With a VC

Transcript

SPEAKER_1: Behavioral science can connect measurable outcomes to real business metrics. Now I want to get into the actual deck. SPEAKER_2: Right place to go next. The key idea is that a behavioral health deck has to do something most decks don't — bridge academic rigor and commercial scalability simultaneously. Investors are asking two questions at once: is the science real, and can this scale? SPEAKER_1: So what are the five slides doing the heaviest lifting? SPEAKER_2: The Problem, Clinical and Outcomes Evidence, Business Model, Unit Economics, and Team. That order is intentional — investors need to feel the urgency before they care about the solution. SPEAKER_1: Let's unpack the clinical and outcomes evidence slide. That's where behavioral founders win or lose credibility fast. SPEAKER_2: Exactly. Investors expect validated outcomes — trial results, symptom scores, adherence rates. Anecdotes don't hold up. But here's the nuance: a thirty percent reduction in symptom severity is compelling science. A twenty percent increase in user retention is what moves a financial model. A strong deck shows how those two connect. SPEAKER_1: So the clinical outcome has to map directly to a business metric. That's the bridge. SPEAKER_2: That's the bridge — and that's where a simple unit-economics framework comes in. Think of it as a two-axis framework. One axis tracks behavioral engagement: are users forming habits? The other tracks revenue impact: does that habit reduce churn, lower acquisition cost, or increase lifetime value? When those align, you have a defensible business. SPEAKER_1: So what someone listening might wonder is — how does a behavioral nudge actually translate into a lower Customer Acquisition Cost? That feels like a leap. SPEAKER_2: Fair question. Suppose a founder's app uses structured if-then planning prompts to keep users engaged daily. Higher engagement means lower dropout. Lower dropout means higher lifetime value. And when satisfied users refer others organically, acquisition cost drops. The nudge isn't just clinical — it's a unit economics driver. SPEAKER_1: Now the deck also needs to prove this can't be replicated by a generic wellness app. How do founders make that case? SPEAKER_2: This is the Scientific Moat. Investors are wary of products that claim differentiation but can't defend it. The answer is specificity — proprietary behavioral algorithms, clinical integrations with health record systems, or outcomes data that took years to generate. Generic apps can copy a feature. They cannot copy a validated dataset or a payer contract. SPEAKER_1: And regulatory classification plays into this too — medical device versus general wellness tool changes the entire timeline. SPEAKER_2: Completely. Sophisticated investors expect founders to address that directly. The regulatory pathway affects time-to-market, cost, and reimbursement strategy. A founder who explains their classification as an advantage — not just a hurdle — signals real execution capability. That connects straight to the reimbursement question: employers, health plans, providers, or consumers? SPEAKER_1: Why do investors prioritize measurable outcomes over product features? Most founders lead with the product. SPEAKER_2: Because features can be copied overnight. Outcomes cannot. A sticky feature keeps someone in the app. A sticky outcome changes their health trajectory — and that creates long-term retention, reduces hospitalizations, and generates the impact metrics investors increasingly demand alongside financial returns. SPEAKER_1: The team slide — why does it carry even more weight in behavioral health than in standard software? SPEAKER_2: Because commercialization cycles here are longer. Cash burn, runway, staged milestones — all of it gets scrutinized harder. A team with complementary clinical and commercial skills signals they can survive that longer path. The science alone doesn't reassure anyone. The people executing it do. SPEAKER_1: So the takeaway for everyone building in this space: the deck isn't just a company summary. It's a designed decision environment. SPEAKER_2: Exactly. The practical move is to map the core clinical claims to financial metrics before the deck is finalized. If a behavioral mechanism can't be traced to retention, acquisition cost, or lifetime value, it belongs in a research paper — not a pitch deck. That's the unit-economics framework in action.